TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE EUROPE LIPID PANEL TESTING MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
2.1 MARKETS COVERED 81
2.2 GEOGRAPHICAL SCOPE 82
2.3 YEARS CONSIDERED FOR THE STUDY 83
2.4 CURRENCY AND PRICING 83
2.5 DBMR TRIPOD DATA VALIDATION MODEL 84
2.6 MULTIVARIATE MODELLING 87
2.7 PRODUCTS & SERVICES LIFELINE CURVE 87
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 88
2.9 DBMR MARKET POSITION GRID 89
2.10 MARKET TESTING TYPE COVERAGE GRID 91
2.11 VENDOR SHARE ANALYSIS 92
2.12 SECONDARY SOURCES 93
2.13 ASSUMPTIONS 93
3 EXECUTIVE SUMMARY 94
4 PREMIUM INSIGHTS 97
4.1 PESTEL ANALYSIS 98
4.2 PORTERS FIVE FORCES 99
4.3 PATENT ANALYSIS 100
5 INDUSTRIAL INSIGHTS 103
5.1 KEY PRICING STRATEGY 103
6 EUROPE LIPID PANEL TESTING MARKET, REGULATIONS 105
6.1 REGULATORY SCENARIO IN EUROPE 105
7 MARKET OVERVIEW 106
7.1 DRIVERS 108
7.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 108
7.1.2 GROWING NUMBER OF CASES OF DYSLIPIDEMIA 109
7.1.3 RAPID CHANGES IN LIFESTYLE CHANGES LEAD TO LIPID DISORDERS 110
7.1.4 RISE IN PREFERENCE FOR HOMECARE TESTING IN LIPID PANEL TESTING 111
7.2 RESTRAINTS 112
7.2.1 STRICT GOVERNMENT REGULATIONS 112
7.2.2 HIGH COST ASSOCIATED WITH TESTING PANELS 113
7.3 OPPORTUNITIES 114
7.3.1 GROWTH IN TECHNOLOGICAL ADVANCEMENTS 114
7.3.2 RISE IN THE PREVALENCE OF OBESITY AMONG PEOPLE 114
7.3.3 INCREASING ADOPTION OF POINT-OF-CARE LIPID PANEL TESTING 115
7.4 CHALLENGES 116
7.4.1 LACK OF SKILLED & CERTIFIED PROFESSIONALS 116
7.4.2 LACK OF STANDARDIZATION OF LIPID PANEL TESTING 116
8 EUROPE LIPID PANEL TESTING MARKET, BY PRODUCTS & SERVICES 118
8.1 OVERVIEW 119
8.2 SERVICES 122
8.2.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 123
8.2.2 TOTAL CHOLESTEROL TEST 123
8.2.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 123
8.2.4 TRIGLYCERIDES/ VLDL TEST 124
8.2.5 NON-HDL CHOLESTEROL TEST 124
8.2.6 OTHERS 125
8.3 KITS 125
8.3.1 STRIPS 126
8.3.1.1 THREE-ANALYTE TEST STRIPS 126
8.3.1.2 DUAL-ANALYTE TEST STRIPS 126
8.3.1.3 SINGLE-ANALYTE TEST STRIPS 126
8.3.2 LANCETS 126
8.3.3 CONTROLS 127
8.3.3.1 MULTI-CHEMISTRY CONTROLS 127
8.3.3.2 HDL CHOLESTEROL CONTROLS 127
8.3.3.3 OTHERS 127
8.3.4 CAPILLARY TUBES 127
8.4 DEVICES 128
8.4.1 BY MODALITY 128
8.4.1.1 STANDALONE 129
8.4.1.2 HANDHELD 129
8.4.1.3 PORTABLE 129
8.4.2 BY TYPE 129
8.4.2.1 LABORATORY BASED 129
8.4.2.2 POINT OF CARE BASED 129
9 EUROPE LIPID PANEL TESTING MARKET, BY PRESCRIPTION MODE 130
9.1 OVERVIEW 131
9.2 PRESCRIPTION-BASED TESTING 134
9.3 OTC-BASED TESTING 135
10 EUROPE LIPID PANEL TESTING MARKET, BY APPLICATION 136
10.1 OVERVIEW 137
10.2 HYPERLIPIDEMIA 140
10.2.1 TOTAL CHOLESTEROL TEST 141
10.2.2 TRIGLYCERIDES/ VLDL TEST 141
10.2.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 141
10.2.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 141
10.2.5 NON-HDL CHOLESTEROL TEST 141
10.2.6 OTHERS 141
10.3 HYPERTRIGLYCERIDEMIA 142
10.3.1 TRIGLYCERIDES/ VLDL TEST 143
10.3.2 TOTAL CHOLESTEROL TEST 143
10.3.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 143
10.3.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 143
10.3.5 NON-HDL CHOLESTEROL TEST 143
10.3.6 OTHERS 143
10.4 ATHEROSCLEROSIS 144
10.4.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 145
10.4.2 TOTAL CHOLESTEROL TEST 145
10.4.3 TRIGLYCERIDES/ VLDL TEST 145
10.4.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 145
10.4.5 NON-HDL CHOLESTEROL TEST 145
10.4.6 OTHERS 145
10.5 FAMILIAL HYPERCHOLESTEROLEMIA 146
10.5.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 147
10.5.2 TOTAL CHOLESTEROL TEST 147
10.5.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 147
10.5.4 TRIGLYCERIDES/ VLDL TEST 147
10.5.5 NON-HDL CHOLESTEROL TEST 147
10.5.6 OTHERS 147
10.6 HYPO LIPOPROTEINEMIA 148
10.6.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 149
10.6.2 HIGH DENSITY LIPOPROTEIN (HDL) TEST 149
10.6.3 TRIGLYCERIDES/ VLDL TEST 149
10.6.4 TOTAL CHOLESTEROL TEST 149
10.6.5 NON-HDL CHOLESTEROL TEST 149
10.6.6 OTHERS 149
10.7 TANGIER DISEASE 150
10.7.1 HIGH DENSITY LIPOPROTEIN (HDL) TEST 151
10.7.2 LOW DENSITY LIPOPROTEIN (LDL) TEST 151
10.7.3 TOTAL CHOLESTEROL TEST 151
10.7.4 TRIGLYCERIDES/ VLDL TEST 151
10.7.5 NON-HDL CHOLESTEROL TEST 151
10.7.6 OTHERS 151
10.8 OTHERS 152
11 EUROPE LIPID PANEL TESTING MARKET, BY END USER 153
11.1 OVERVIEW 154
11.2 HOSPITAL 157
11.2.1 BY TYPE 157
11.2.1.1 PRIVATE 158
11.2.1.1.1 SERVICES 158
11.2.1.1.2 KITS 158
11.2.1.1.3 DEVICES 158
11.2.1.2 PUBLIC 158
11.2.1.2.1 SERVICES 159
11.2.1.2.2 KITS 159
11.2.1.2.3 DEVICES 159
11.2.2 BY TIER 159
11.2.2.1 TIER 1 159
11.2.2.1.1 SERVICES 160
11.2.2.1.2 KITS 160
11.2.2.1.3 DEVICES 160
11.2.2.2 TIER 2 160
11.2.2.2.1 SERVICES 160
11.2.2.2.2 KITS 160
11.2.2.2.3 DEVICES 160
11.2.2.3 TIER 3 160
11.2.2.3.1 SERVICES 161
11.2.2.3.2 KITS 161
11.2.2.3.3 DEVICES 161
11.3 DIAGNOSTIC CLINICS 161
11.3.1 SERVICES 162
11.3.2 KITS 162
11.3.3 DEVICES 162
11.4 SPECIALTY CLINICS & PHYSICIAN OFFICES 163
11.4.1 SERVICES 164
11.4.2 KITS 164
11.4.3 DEVICES 164
11.5 REFERENCE LABORATORIES 164
11.5.1 SERVICES 165
11.5.2 KITS 165
11.5.3 DEVICES 165
11.6 AMBULATORY SURGICAL CENTERS 165
11.6.1 SERVICES 166
11.6.2 KITS 166
11.6.3 DEVICES 166
11.7 PATHOLOGY LABORATORIES 167
11.7.1 SERVICES 168
11.7.2 KITS 168
11.7.3 DEVICES 168
11.8 ACADEMIC AND RESEARCH INSTITUTES 168
11.8.1 SERVICES 169
11.8.2 KITS 169
11.8.3 DEVICES 169
11.9 OTHERS 170
12 EUROPE LIPID PANEL TESTING MARKET, BY DISTRIBUTION CHANNEL 171
12.1 OVERVIEW 172
12.2 DIRECT TENDER 175
12.3 RETAIL PHARMACY 175
12.3.1 HOSPITAL PHARMACIES 176
12.3.2 DRUG STORES 176
12.3.3 OTHERS 176
12.4 ONLINE SALES 177
12.5 OTHERS 178
13 EUROPE LIPID PANEL TESTING MARKET, BY REGION 179
13.1 EUROPE 180
13.1.1 U.K. 194
13.1.2 GERMANY 204
13.1.3 FRANCE 214
13.1.4 RUSSIA 224
13.1.5 ITALY 234
13.1.6 SPAIN 244
13.1.7 TURKEY 254
13.1.8 NETHERLANDS 264
13.1.9 SWITZERLAND 274
13.1.10 REST OF EUROPE 284
14 EUROPE LIPID PANEL TESTING MARKET, COMPANY LANDSCAPE 285
14.1 COMPANY SHARE ANALYSIS: EUROPE 285
15 SWOT ANALYSIS 286
16 EUROPE LIPID PANEL TESTING MARKET, COMPANY PROFILE 287
16.1 QUEST DIAGNOSTICS INCORPORATED 287
16.1.1 COMPANY SNAPSHOT 287
16.1.2 REVENUE ANALYSIS 288
16.1.3 COMPANY SHARE ANALYSIS 288
16.1.4 PRODUCT PORTFOLIO 289
16.1.5 RECENT DEVELOPMENTS 289
16.2 EUROFINS SCIENTIFIC 290
16.2.1 COMPANY SNAPSHOT 290
16.2.2 REVENUE ANALYSIS 290
16.2.3 COMPANY SHARE ANALYSIS 291
16.2.4 PRODUCT PORTFOLIO 291
16.2.5 RECENT DEVELOPMENT 291
16.3 LABORATORY CORPORATION OF AMERICA HOLDINGS 292
16.3.1 COMPANY SNAPSHOT 292
16.3.2 REVENUE ANALYSIS 292
16.3.3 COMPANY SHARE ANALYSIS 293
16.3.4 PRODUCT PORTFOLIO 293
16.3.5 RECENT DEVELOPMENT 294
16.4 F. HOFFMANN-LA ROCHE LTD. 295
16.4.1 COMPANY SNAPSHOT 295
16.4.2 REVENUE ANALYSIS 295
16.4.3 COMPANY SHARE ANALYSIS 296
16.4.4 PRODUCT PORTFOLIO 296
16.4.5 RECENT DEVELOPMENT 296
16.5 RANDOX LABORATORIES LTD. 297
16.5.1 COMPANY SNAPSHOT 297
16.5.2 COMPANY SHARE ANALYSIS 297
16.5.3 PRODUCT PORTFOLIO 298
16.5.4 RECENT DEVELOPMENT 298
16.6 ABBOTT 299
16.6.1 COMPANY SNAPSHOT 299
16.6.2 REVENUE ANALYSIS 299
16.6.3 COMPANY SHARE ANALYSIS 300
16.6.4 PRODUCT PORTFOLIO 300
16.6.5 RECENT DEVELOPMENT 301
16.7 AWARENESS TECHNOLOGY, INC. 302
16.7.1 COMPANY SNAPSHOT 302
16.7.2 PRODUCT PORTFOLIO 302
16.7.3 RECENT DEVELOPMENTS 302
16.8 ARUP LABORATORIES 303
16.8.1 COMPANY SNAPSHOT 303
16.8.2 PRODUCT PORTFOLIO 303
16.8.3 RECENT DEVELOPMENT 303
16.9 BIO-RAD LABORATORIES, INC. 304
16.9.1 COMPANY SNAPSHOT 304
16.9.2 REVENUE ANALYSIS 304
16.9.3 PRODUCT PORTFOLIO 305
16.9.4 RECENT DEVELOPMENT 305
16.10 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER) 306
16.10.1 COMPANY SNAPSHOT 306
16.10.2 REVENUE ANALYSIS 306
16.10.3 PRODUCT PORTFOLIO 307
16.10.4 RECENT DEVELOPMENT 307

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.